Scholarlink

Background <p>Mass vaccination efforts worldwide have reduced the incidence of COVID-19, but despite this reduction, seroconversion studies in sub-Saharan Africa are limited. The aim of this study is to assess the incidence of seroconversion in subjects who received the first dose of SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa.</p> Methods <p>This was a prospective study recruiting 918 subjects vaccinated at the Cliniques Universitaires de Kinshasa between 19 April and 14 August 2021. Sociodemographic, haematological, biochemical and serological data were collected. Cox proportional hazards were used to identify predictors of seroconversion with a threshold of <i>p</i> &lt; 0.05.</p> Results <p>Of the 918 vaccinated individuals, 69.3% were men with a mean age of 47.4 ± 16.0&#xa0;years. The incidence of seroconversion at last follow-up was 3.00 per 100 P-D. Patients receiving Pfizer (aRR: 3.19; 95% CI: 2.62–3.88) and Modern (aRR: 1.91; 95% CI: 1.60–2.29) vaccines, men (aRR: 2.03; 95% CI: 1.89–3.20), those with comorbidities (aRR: 2.38; 95% CI: 1.89–3.21); subjects with normal creatinine (aRR: 2.08; 95% CI: 1.88–3.32) and normal ALT (aRR: 3.04; 95% CI: 1.89–4.22) were the factors independently predicting seroconversion.</p> Conclusion <p>The vaccines used had conferred significant immunity on subjects upon receipt of the first dose. This immunity appears to be greater when using the mRNA vaccine than when using the inactivated vaccine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月11日

查看全文
  • Eric Kasongo Mukenge,
  • Blaise Matondo-Manzambi Sumbu,
  • Aliocha Natuhoyila Nkodila,
  • Jeremie Masidi Muwonga,
  • Jean-Robert Rissassi Makulo,
  • Mamy Zita Ngole,
  • Ben Izizag Bepouka,
  • Murielle Mashi Longokolo,
  • Guyguy Kamwiziku,
  • Hippolyte Nanituma Situakibanza,
  • Jean-Marie Ntumba Kayembe,
  • Benjamin Longo-Mbenza,
  • George Lelo Mvumbi,
  • Baudouin Buassa-Bu-Tsumbu,
  • Jean Claude Makangara,
  • Désire Kulimba Mashinda,
  • Eric Musalu Mafuta,
  • Donatien Sonzi Mangala,
  • Mireille Nganga Nkanga,
  • Gustave Ntita Ilunga,
  • Fonce Tshibawu Nkunda,
  • Christian Nsimba Lengo,
  • Steve Mundeke Ahuka

摘要

Background

Mass vaccination efforts worldwide have reduced the incidence of COVID-19, but despite this reduction, seroconversion studies in sub-Saharan Africa are limited. The aim of this study is to assess the incidence of seroconversion in subjects who received the first dose of SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa.

Methods

This was a prospective study recruiting 918 subjects vaccinated at the Cliniques Universitaires de Kinshasa between 19 April and 14 August 2021. Sociodemographic, haematological, biochemical and serological data were collected. Cox proportional hazards were used to identify predictors of seroconversion with a threshold of p < 0.05.

Results

Of the 918 vaccinated individuals, 69.3% were men with a mean age of 47.4 ± 16.0 years. The incidence of seroconversion at last follow-up was 3.00 per 100 P-D. Patients receiving Pfizer (aRR: 3.19; 95% CI: 2.62–3.88) and Modern (aRR: 1.91; 95% CI: 1.60–2.29) vaccines, men (aRR: 2.03; 95% CI: 1.89–3.20), those with comorbidities (aRR: 2.38; 95% CI: 1.89–3.21); subjects with normal creatinine (aRR: 2.08; 95% CI: 1.88–3.32) and normal ALT (aRR: 3.04; 95% CI: 1.89–4.22) were the factors independently predicting seroconversion.

Conclusion

The vaccines used had conferred significant immunity on subjects upon receipt of the first dose. This immunity appears to be greater when using the mRNA vaccine than when using the inactivated vaccine.